RxDoctor Payments Data

Ann Hill, MD

Dermatology · Birmingham, ALNPI 1679507727

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,550 of the $56,105 with a category attached, or 88.3%. Galderma Laboratories, L.p. accounts for 90.0% of it on its own, with 22 other manufacturers making up the rest.

$56,105in general payments, 2019–2025

Across 337 payments — averaging $166.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$50K
  • AbbVie$2K
  • Johnson & Johnson$642
  • LEO Pharma Inc.$458
  • Pfizer$339
  • Novartis$317
  • plus $2K from 17 others

What the payments were for

  • Speaking & faculty fees$49,55088%
  • Food & beverage$6,28211%
  • Education$2730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,105 in reported general payments places this provider in the 85th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$192,088
Medicare patients
708
Services billed
3,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab28$205,932
Humira(Cf) PenAdalimumab13$205,227
RinvoqUpadacitinib15$103,843
Dupixent PenDupilumab28$103,488
Dupixent SyringeDupilumab24$89,122
Clobetasol Propionate228$12,161
Tacrolimus47$7,179
Fluorouracil79$6,517
Halobetasol Propionate71$5,606
Tretinoin42$3,437
Metronidazole53$3,264
Betamethasone Dipropionate75$3,134
Triamcinolone Acetonide176$2,958
Doxycycline Hyclate116$2,856
Clindamycin Phosphate49$2,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,551$103,84315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 168 dermatology providers in Alabama.

Other dermatology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →